CJC No DAC Ipamorelin Spray combines CJC-1295 without DAC, a growth-hormone-releasing hormone (GHRH) analog, with Ipamorelin, a selective growth hormone secretagogue that activates the GHS-R1a receptor. Researchers use CJC No DAC Ipamorelin Spray to model synergistic pulses of endogenous growth hormone release in cell and animal studies. For background reading, see our CJC-1295 and Ipamorelin research guide.
Detailed Mechanism of Action
CJC No DAC Ipamorelin Spray works through two complementary receptor pathways. The CJC No DAC component is a GHRH analog that binds the GHRH receptor on pituitary somatotrophs, activating a cAMP-dependent cascade that triggers growth hormone synthesis and release. Unlike the DAC-modified version, CJC No DAC has a shorter half-life of roughly 30 minutes, producing a sharper, more natural-looking GH pulse in research models.
The Ipamorelin component in this spray is a pentapeptide that mimics ghrelin at the GHS-R1a receptor. It is prized in research settings for its selectivity: unlike older secretagogues such as GHRP-6, Ipamorelin does not meaningfully elevate cortisol, prolactin, or ACTH in study models, allowing researchers to isolate GH-specific effects.
When combined, the GHRH and GHS pathways activated by CJC No DAC Ipamorelin Spray produce a synergistic increase in GH pulse amplitude that is greater than either compound alone, a mechanism researchers attribute to simultaneous receptor activation on the same somatotroph cell population.
Because both mechanisms converge on the same somatotroph cell without directly competing for a single receptor site, models using this spray often show a pulsatile secretion pattern that more closely resembles natural nocturnal GH release than continuous-infusion designs. Researchers studying receptor desensitization also use paired GHRH/GHS protocols to compare downregulation kinetics against single-agent controls, since repeated stimulation of the GHRH receptor alone can blunt responsiveness over time in ways that combined signaling may partially offset.
Understanding the GHRH and Ghrelin Mimetic Pathways
Growth hormone release in the body is governed by two separate but converging signaling systems. The hypothalamus releases natural GHRH to stimulate the pituitary directly, while a separate ghrelin pathway modulates the amplitude and timing of each secretory pulse. Research-grade GHRH analogs and ghrelin mimetics were developed specifically to let scientists probe these pathways independently or in combination.
Because CJC No DAC Ipamorelin Spray engages both systems at once, it gives researchers a single tool to study pathway interaction rather than needing two separate compounds administered on different schedules. This is one reason combination formulations have become popular in endocrinology research over the past decade.
Published Research
Foundational human trials on the CJC-1295 backbone found prolonged stimulation of GH and IGF-1 secretion following GHRH analog administration in healthy adults, supporting the rationale behind CJC No DAC Ipamorelin Spray research protocols (Teichman et al., J Clin Endocrinol Metab, 2006).
Separately, Ipamorelin was characterized as the first selective growth hormone secretagogue, distinguishing it from earlier GHRPs by its lack of effect on cortisol and prolactin (Raun et al., Eur J Endocrinol, 1998).
More recent clinical work on combined GHRH/GHS secretagogue treatment found measurable increases in serum IGF-1, reinforcing why researchers pair both mechanisms in a single spray formulation (Sigalos et al., Am J Mens Health, 2017).
Taken together, these three papers span nearly two decades of endocrinology research and form the scientific basis researchers cite when designing new protocols around GHRH-analog and ghrelin-mimetic combinations. None of the cited studies evaluated a spray delivery format directly, so researchers using this product typically treat absorption kinetics as a distinct variable worth characterizing in their own study design rather than assuming equivalence to injected or oral dosing.
Who Uses CJC No DAC Ipamorelin Spray in Research
Laboratories studying the somatotropic axis, endocrinology departments modeling pulsatile hormone release, and longevity-focused research groups investigating GH/IGF-1 signaling are the primary users of CJC No DAC Ipamorelin Spray. Its needle-free format also appeals to research settings where repeated injections across a study cohort would introduce additional variables or handling burden.
Academic groups comparing delivery-route pharmacokinetics sometimes run this spray alongside injectable formulations of the same peptides to characterize differences in absorption and onset, since sublingual mucosal absorption follows a different pathway than subcutaneous injection. Smaller university labs also favor the format because it removes sharps disposal requirements from short-term studies.
CJC No DAC Ipamorelin Spray vs Alternatives
Choosing between delivery formats matters for study design. The table below compares CJC No DAC Ipamorelin Spray against a traditional injectable vial blend and against MK-677, an orally active but non-selective secretagogue.
| Feature | CJC No DAC Ipamorelin Spray | Injectable CJC/Ipamorelin Vial | MK-677 Oral Secretagogue |
|---|
| Delivery Method | Sublingual spray | Subcutaneous injection | Oral capsule |
| Reconstitution Needed | No | Yes | No |
| Dosing Precision | Metered per spray | Syringe-measured | Fixed capsule dose |
| Receptor Selectivity | GHRH + GHS-R1a | GHRH + GHS-R1a | GHS-R1a only |
| Needle-Free | Yes | No | Yes |
| Typical Research Half-Life | ~30 min (CJC portion) | ~30 min (CJC portion) | ~24 hours |
| Storage | Refrigerate after opening | Refrigerate after reconstitution | Room temperature |
No single format is universally superior; the right choice depends on the study’s tolerance for injection-related handling, the need for exact receptor selectivity, and whether absorption route itself is a study variable. Many labs keep both an injectable blend and a spray on hand so they can match delivery format to the specific protocol.
Application & Handling Protocol
Most lab protocols for CJC No DAC Ipamorelin Spray call for priming the pump before first use, then administering the labeled number of sprays sublingually and holding briefly before swallowing. Because each spray delivers a fixed 50mcg + 50mcg dose, researchers can log intake precisely across a study timeline without weighing or measuring liquid volumes.
- Prime the pump with a few test sprays into a tissue before the first recorded dose.
- Administer directly under the tongue and hold for 20-30 seconds per common lab protocols.
- Record the exact spray count per session in the study log for reproducibility.
- Store the bottle upright and refrigerated between sessions to protect peptide integrity.
Researchers tracking dosing schedules across a study cohort often reference our peptide dosage calculator guide and peptide half-life chart when comparing spray timing to injectable protocols.
Dosing Considerations for Study Design
Because CJC No DAC Ipamorelin Spray delivers a fixed micrograms-per-spray amount, protocol authors typically define dosing in terms of spray count rather than milligrams, then convert to total peptide mass for record-keeping. Researchers should account for sublingual absorption variability between subjects, which can differ from the more consistent bioavailability seen with subcutaneous injection.
Study designs that compare dosing across multiple timepoints often standardize administration timing relative to sleep onset, since endogenous GH pulses are naturally tied to the first slow-wave sleep cycle, and researchers frequently reference our peptide cycling guide when planning multi-week protocols.
Research Considerations and Best Practices
As with any combination peptide research tool, protocol authors are encouraged to run pilot batches before committing to a full study cohort, since individual variability in sublingual absorption can be more pronounced than with injectable routes. Keeping a detailed log of spray counts, timing, and any observed variance helps normalize results across a larger dataset.
Many teams also cross-reference their planned CJC No DAC Ipamorelin Spray protocol against existing published dosing ranges for the individual peptides before finalizing a study-specific schedule, adjusting for the sublingual route rather than assuming direct equivalence to injected dosing curves.
Peptide Glossary
- GHRH: Growth-hormone-releasing hormone, the natural hypothalamic signal that triggers pituitary GH release.
- GHS-R1a: The ghrelin receptor subtype activated by secretagogues like Ipamorelin.
- IGF-1: Insulin-like growth factor 1, a downstream marker commonly measured in GH axis research.
- Pulsatile secretion: The natural pattern of hormone release in discrete bursts rather than a steady stream.
- Somatotroph: The pituitary cell type responsible for producing and releasing growth hormone.
Common Research Endpoints Measured
Studies involving GHRH-analog and ghrelin-mimetic combinations typically track serum GH pulse amplitude and frequency, downstream IGF-1 levels, and body composition markers over the study period. Some protocols also measure sleep-stage duration, since natural GH secretion peaks during slow-wave sleep, while others track receptor sensitivity over repeated dosing cycles to watch for desensitization trends.
Blood draw timing relative to dose administration is a critical variable in these study designs, since GH pulses are short-lived and can be missed entirely if sampling intervals are too widely spaced. Researchers often pilot a dense sampling schedule in early study phases before settling on a sparser protocol for the full cohort.
Documenting Results for Reproducibility
Because peptide research depends heavily on consistent handling, many labs standardize a documentation template covering batch number, storage conditions, dose timing, and any deviations from protocol. This is particularly useful when comparing results across multiple cohorts or when publishing findings that other labs may attempt to replicate.
Pairing this documentation with the batch-specific Certificate of Analysis helps ensure that any variance observed in results can be traced back to a specific, verifiable source material rather than an unknown quality issue.
Additional Glossary Terms
- Bioavailability: The proportion of an administered dose that reaches systemic circulation intact.
- Sublingual absorption: Uptake of a compound through the mucous membranes under the tongue, bypassing first-pass liver metabolism.
- Desensitization: A reduction in receptor responsiveness following repeated or prolonged stimulation.
- Cold-chain packaging: Shipping materials designed to maintain refrigeration temperatures in transit.
Storage & Stability
Keep CJC No DAC Ipamorelin Spray refrigerated at 2-8°C once opened, and store away from direct light and heat to preserve peptide stability. Unopened bottles should remain refrigerated until first use. Full guidance is available in our peptide storage guide.
Certificate of Analysis
Every batch of CJC No DAC Ipamorelin Spray ships with an independent Certificate of Analysis confirming purity and identity via HPLC and mass spectrometry. New to reading these reports? Our COA reading guide walks through each section so researchers can verify batch-specific results before starting a study.
Quality & Sourcing Standards
PSPeptides sources raw material for CJC No DAC Ipamorelin Spray from US-based manufacturing partners and requires independent lab verification before any batch is released for sale. This two-step verification process is part of why many labs choose PSPeptides over suppliers that rely solely on in-house testing. Our guide to choosing a research peptide supplier explains what to look for when comparing vendors.
Shipping & Handling Upon Arrival
Orders containing CJC No DAC Ipamorelin Spray ship with cold-chain packaging appropriate for peptide products. Refrigerate the bottle immediately upon arrival, even if the outer packaging feels cool to the touch, and inspect the spray pump for damage before first use. Contact support promptly if a bottle arrives visibly compromised.
Planning a Multi-Week Research Timeline
Longer study designs involving CJC No DAC Ipamorelin Spray typically span four to twelve weeks, with researchers building in periodic assessment points to track GH and IGF-1 trends over time rather than relying on a single endpoint measurement. Baseline bloodwork before the first dose gives researchers a reference point against which later timepoints can be compared.
Mid-study check-ins are common practice, allowing protocol authors to catch unexpected variance early and adjust sampling frequency if the data suggests a pulse pattern different from what was anticipated. Many teams also build in a washout period at the end of a study before any follow-up dosing phase, giving the GH axis time to return to baseline and reducing the risk of carryover effects confounding a subsequent phase.
Whatever the timeline, consistent record-keeping from day one makes it far easier to interpret results at the end of a study and to compare outcomes against previously published GHRH and ghrelin-mimetic research.
Why Researchers Choose PSPeptides
- US Manufactured
- Third-Party Tested: Independent HPLC and mass spectrometry on every batch
- Fast Shipping: Free UPS 2nd Day Air over $150, same-day before 2 PM EST
- Flexible Payments: Credit cards, Afterpay, Klarna, Apple Pay, Google Pay
- 7-Day Support: Email, phone, or text
Frequently Asked Questions
Is CJC No DAC Ipamorelin Spray comparable to injectable versions in research settings?
Both deliver the same GHRH and GHS-R1a receptor activity. The spray offers needle-free, pre-metered dosing, while injectable vials require reconstitution and syringe measurement, so the choice often comes down to protocol preference.
How is CJC No DAC Ipamorelin Spray typically dosed in research protocols?
Each spray delivers 50mcg CJC No DAC plus 50mcg Ipamorelin. Researchers follow their protocol’s specified spray count per session and log totals against the 100-spray bottle.
Does CJC No DAC Ipamorelin Spray need refrigeration?
Yes. Refrigerate after opening and keep away from light and heat to protect peptide stability throughout the labeled use period.
What distinguishes CJC No DAC from CJC-1295 with DAC?
CJC No DAC lacks the Drug Affinity Complex modification, giving it a shorter half-life and a sharper GH pulse profile that many researchers prefer for pulsatile-release study designs over the extended-release DAC version.
Can this spray be used alongside other research peptides?
Some protocols pair GH secretagogues with recovery-focused peptides for combined-pathway studies. Researchers should consult their own institutional protocols before designing multi-peptide study arms.
How should unused product be handled at the end of a study?
Follow institutional disposal protocols for research compounds. Keep the bottle sealed, refrigerated, and labeled with batch information until disposal or the next scheduled use.
Is a Certificate of Analysis available for every batch of CJC No DAC Ipamorelin Spray?
Yes. Every batch is independently tested and shipped with a batch-specific Certificate of Analysis so researchers can verify purity and identity before use.
What research areas commonly cite GHRH and ghrelin-mimetic combination studies?
Beyond core endocrinology, published work in this space has informed research directions in metabolic health, recovery physiology, and aging biology, since the GH/IGF-1 axis intersects with all three fields. Researchers new to the area often start with the foundational trials cited above before designing their own combination protocols.
Related Resources
All PSPeptides products, including CJC No DAC Ipamorelin Spray, are sold exclusively for laboratory and research use. Not intended for human consumption.
Made & Shipped
